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Abstract Microdeletions and microduplications encom-
passing a ~593-kb region of 16p11.2 have been implicated
as one of the most common genetic causes of susceptibility
to autism/autism spectrum disorder (ASD). We report 45
microdeletions and 32 microduplications of 16p11.2,
representing 0.78% of 9,773 individuals referred to our
laboratory for microarray-based comparative genomic
hybridization (aCGH) testing for neurodevelopmental and
congenital anomalies. The microdeletion was de novo in 17
individuals and maternally inherited in five individuals for
whom parental testing was available. Detailed histories of
18 individuals with 16p11.2 microdeletions were reviewed;
all had developmental delays with below-average intelli-
gence, and a majority had speech or language problems or
delays and various behavioral problems. Of the 16
individuals old enough to be evaluated for autism, the
speech/behavior profiles of seven did not suggest the need
for ASD evaluation. Of the remaining nine individuals who
had speech/behavior profiles that aroused clinical suspicion
of ASD, five had formal evaluations, and three had PDD-
NOS. Of the 19 microduplications with parental testing,
five were de novo, nine were maternally inherited, and five
were paternally inherited. A majority with the micro-
duplication had delayed development and/or specific
deficits in speech or language, though these features were
not as consistent as seen with the microdeletions. This
study, which is the largest cohort of individuals with
16p11.2 alterations reported to date, suggests that 16p11.2
microdeletions and microduplications are associated with a
high frequency of cognitive, developmental, and speech
delay and behavior abnormalities. Furthermore, although
features associated with these alterations can be found in
individuals with ASD, additional factors are likely required
to lead to the development of ASD.
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Introduction
Only 10–20% of individuals with ASD have a known
etiology, which includes single-gene disorders and cytoge-
netic abnormalities (Abrahams and Geschwind 2008). This
has prompted a search for additional genetic susceptibility
loci. Several such studies discovered a recurrent ~593-kb
microdeletion flanked by segmental duplications at 16p11.2
in multiple affected individuals (AUTS14, OMIM 611913),
although three of these studies identified the microdeletion
in the same four families from the Autism Genetic
Resource Exchange (AGRE) (Sebat et al. 2007; Kumar et
al. 2008; Weiss et al. 2008; Christian et al. 2008; Marshall
et al. 2008). Screening studies have estimated the preva-
lence of either the microdeletion or microduplication to be
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DOI 10.1007/s11689-009-9037-4approximately 1% of individuals with autism (15/1740, 4/
397, and 4/427 individuals with ASD) (Weiss et al. 2008;
Christian et al. 2008; Marshall et al. 2008). Numerous
studies suggest variability in expressivity and penetrance.
The microdeletion has been reported in individuals with
cognitive impairment but without autism (Ghebranious et
al. 2007; Rosenberg et al. 2006; Shiow et al. 2008; Bijlsma
et al. 2009); in 1.76% (9/512) of children (including two
monozygotic twins) with mental retardation, developmental
delay or ASD (Weiss et al. 2008); in 0.33% (14/4284) of
patients with mental retardation or multiple congenital
anomalies (Bijlsma et al. 2009) ;a n di n1 . 2 3 %( 1 / 8 1 )o f
another smaller sample of individuals with mental retar-
dation, dysmorphic features and a normal karyotype
(Rosenberg et al. 2006). Moreover, both events have been
found in control populations, including a group that
contained individuals with bipolar disorder and a popula-
tion of 19,000 unscreened individuals (Table 1)( W e i s se t
al. 2008). The detection of this microdeletion and micro-
duplication in parents, in control populations (Kumar et al.
2008; Weiss et al. 2008; Bijlsma et al. 2009; Fernandez et
al. 2009;G l e s s n e re ta l .2009) and in non-autistic
individuals (Ghebranious et al. 2007; Rosenberg et al.
2006; Shiow et al. 2008; Bijlsma et al. 2009; Walsh et al.
2008), as well as the lack of clinical details in individuals
classified with autism poses a challenge for diagnosis and
research. Furthermore, only two studies have explored the
broader phenotypes of these individuals in-depth (Bijlsma
et al. 2009;F e r n a n d e ze ta l .2009). Therefore, in the
largest study to date, we characterized the clinical features
associated with microdeletions and microduplications of
16p11.2 to provide a genotype-phenotype correlation of
individuals with these events.
Results
Between November 2007 and October 2008, we analyzed
9,773 individuals, 820 of whom had an ASD as the
indication for study, using whole-genome bacterial artificial
chromosome or oligonucleotide microarrays with expanded
coverage of 16p11.2. Other indications for study among
these individuals were developmental delays, dysmorphic
features, congenital anomalies, and/or seizures. We identi-
fied 45 microdeletions (0.46%) encompassing 16p11.2
(Table 2). Six (0.73%) of the 820 individuals with an
ASD as the indication for study had the microdeletion.
Three of these 45 individuals had another clinically
significant finding on aCGH and were excluded from
further study (Table 3). Analysis of the microdeletions
using an ultra high-density NimbleGen array with 120,146
probes within 16p11.2 confirmed a 548-kb common
interval spanning chr16:29559100-30107210 (Hg18)
(Fig. 1). This common interval encompasses about 29
genes (see Supplemental Note and Table S1). High-
resolution aCGH also showed that the proximal and distal
breakpoints of the 16p11.2 rearrangement map within
highly identical clusters of segmental duplications
(Fig. 1). Within these segmental duplication clusters, two
highly homologous directly oriented duplication blocks
were identified. These duplication blocks are 147 kb and
72 kb in size with a sequence identity of 99.5% and 98.7%,
respectively, and map to both the proximal and distal
breakpoints according to the UCSC Genome Browser,
Hg18, Build 36 (Table S2). Misalignment of these directly
oriented homologous segmental duplication blocks flanking
the disease-associated 16p11.2 genomic region, during
meiosis potentially predisposes to non-allelic homologous
recombination (NAHR) events resulting in microdeletions
or microduplications (Lupski 1998).
For the 45 individuals with the 16p11.2 microdeletion,
29 maternal samples and 19 paternal samples were tested,
and inheritance was determined in 22 individuals. The
microdeletion was de novo in 17 individuals (77%) and was
maternally inherited in five individuals (23%). One of these
mothers was reported to be normal; another mother had
mental retardation, schizophrenia, and Tourette syndrome; a
thirdhadintellectualimpairment; andafourthhadshort-term
memory loss secondary to accidental trauma but no history
of delays. Information was unavailable on the fifth mother.
Detailed clinical information was available for 18
individuals with microdeletions in our cohort (Table 4,
Table S3). The majority of individuals had minimal
dysmorphic features, and these features were variable
(Fig. 2). Ear abnormalities were the most common, with
eight subjects (44%) with fleshy or prominent ears and four
subjects (22%) with hypoplastic or simple ears. Major
organ defects were uncommon in our study population,
although three had aortic abnormalities: either abnormal
aortic valves, hypoplastic aortic arch, or enlarged aortas.
One individual reported here has a history of seizures, a
second has staring spells, and a third has an abnormal EEG
without seizure activity. All 18 individuals had develop-
mental delays with below-average intelligence. A majority
of the individuals (94%) had speech problems or delays,
including speech delays greater than other delays, poor
articulation, lower verbal intelligence and difficulty in
reading skills. Fourteen of the individuals in our population
(78%) were reported to have some type of behavioral
problem, most commonly attention deficit-hyperactivity
disorder (ADHD) or poor attention span (44%) and
aggression or outbursts (39%).
Of the 16 individuals with the microdeletion old enough
to be evaluated for autism, seven were not described as
autistic and had not had ASD testing. Although a majority
of these individuals had speech delay, their behavioral
J Neurodevelop Disord (2010) 2:26–38 27Table 1 Frequency of 16p11.2 microdeletions and microduplications reported in large-scale population studies
Authors Population Frequency
of
16p11.2
deletion
Percent Sum Frequency
of
16p11.2
duplication
Percent Sum
ASD Cohorts
Sebat et al. (2007)
a Sporadic ASD 1/118 0.85% 0.51% 0/118 0.00% 0.00%
47 multiplex ASD families 0/77 0.00% 0/77 0.00%
Kumar et al. (2008) Sporadic autism 0/87 0.00% 0.56% 1/712 0.14% 0.14%
625 multiplex autism families 4/625
b 0.64%
Weiss et al. (2008) 751 multiplex autism families 5/1441
b 0.35% 0.46% 7/1441 0.49% 0.40%
Icelandic patients with ASD 3/299 1.00% 0/299 0.00%
Christian et al. (2008)
c Sporadic ASD 0/35 0.00% 1.01%
362 multiplex ASD families 4/362
b 1.10%
Marshall et al. (2008) Sporadic ASD 1/238 0.42% 0.47% 1/238 0.42% 0.47%
189 multiplex ASD families 1/189 0.53% 1/189 0.53%
Glessner et al. (2009)
d Sporadic & familial autism 3/859 0.35% 0.36% 2/859 0.23% 0.41%
Sporadic & familial ASD 5/1336
b 0.37% 7/1336 0.52%
Other cohorts
This study Patients referred for clinical aCGH testing with
ASD indication
6/820 0.73% 0.46% 3/820 0.37% 0.33%
Patients referred for clinical aCGH testing without
ASD indication
39/8953 0.44% 29/8953 0.32%
Rosenberg et al .(2006) Patients with mental retardation, dysmorphic features,
and normal karyotype
1/81 1.23% 1.23% 0/81 0.00% 0.00%
Weiss et al. (2008) Icelandic patients with schizophrenia, bipolar disorder,
ADHD, panic disorder, anxiety, depression, addiction,
or dyslexia
5/5019 0.10% 0.10% 2/5019 0.04% 0.04%
Children with mental retardation, developmental delay,
or ASD
5/512
e 0.98% 0.98% 4/512 0.78% 0.78%
Walsh et al. (2008) Patients with childhood-onset schizophrenia and IQ ≥70. 0/83 0.00% 0.00% 2/83 2.41% 2.41%
Bijlsma et al. (2009) Patients with MR/MCA 14/4284 0.33% 0.33%
Controls
f
This study; Itsara et al.
(2009)
936 middle-aged Americans, 671 NINDS samples,
886 HGDP samples
0/2393 0.00% 0.00% 1/2393 0.04% 0.04%
Sebat et al. (2007)
a Unaffected siblings of individuals with ASD 0/76 0.00% 0.00% 0/76 0.00% 0.00%
99 families without autism 0/120 0.00% 0/120 0.00%
Kumar et al. (2008) NIMH controls 0/837 0.00% 0.00% 2/837 0.24% 0.24%
Weiss et al. (2008) Parents from multiplex autism families 0/1420 0.00% 0.02% 2/1420 0.14% 0.03%
1087 individuals with bipolar disorder +1727 NIMH
controls
3/2814 0.11% 0/2814 0.00%
Children's Hospital patients without developmental
delay, mental retardation, or ASD
0/434 0.00% 0/434 0.00%
Unscreened Icelandic individuals 2/18834 0.01% 5/18834 0.03%
Christian et al. (2008)
c NIMH controls 0/372 0.00% 0.00%
Marshall et al., Fernandez et
al. (2008; 2009)
German blood donors & Canadians >age 60 in coronary
artery disease study
0/2387 0.00% 0.00% 0/2387 0.00% 0.00%
Walsh et al. (2008) Non-transmitted chromosomes of parents of sample of children
with childhood-onset schizophrenia
0/77 0.00% 0.00% 0/77 0.00% 0.00%
Glessner et al. (2009)
d, g Well, ASD-free, Caucasian children 4/2519 0.16% 0.16% 4/2519 0.16% 0.16%
aOnly reporting de novo events
bThese represent the same 5 individuals from 4 AGRE families.
cOnly reporting genomic imbalances not found in controls
dIncludes smaller deletions and duplications within the interval
eIncludes a set of monozygotic twins
fSome reported controls are from the same populations and may not be independent.
gThis group has since published their control set, which does not contain any 16p11.2 abnormalites (Shaikh et al. 2009).
28 J Neurodevelop Disord (2010) 2:26–38Table 2 Microdeletions and microduplications of 16p11.2 identified by our laboratory
Total individuals Individuals referred for ASD
a Individuals not referred for ASD
b p-value
c
Number 9773 820 8953
16p11.2 microdeletion 45 (0.46%) 6 (0.73%) 39 (0.44%) 0.271
de novo 17 2 15
maternally inherited 5 0 5
paternally inherited 0 0 0
unknown (parents not tested) 23 4 19
16p11.2 microduplication 32 (0.33%) 3 (0.37%) 29 (0.32%) 0.748
de novo 51 4
maternally inherited 9 0 9
paternally inherited 5 0 5
unknown (parents not tested) 13 2 11
Total 16p11.2 abnormalities 77 (0.78%) 9 (1.1%) 68 (0.76%) 0.298
aIndividuals referred for autism, autistic features, PDD, or Asperger syndrome
bAll other individuals not listing an ASD as an indication for study; this does not rigorously exclude individuals with ASD
cA comparison of frequencies in the ASD and non-ASD groups, using Fisher’s exact test, two-tailed.
Table 3 Indications for study in 45 individuals found to have the 16p11.2 microdeletion
Asperger syndrome
Autism (2)
Autism, failure to thrive, multiple exostosis syndrome
Borderline newborn screening, failure to thrive, altered mental status
Chromosome Y deletion
Congenital anomaly
Developmental delay (1) (1) (6)
Developmental delay, autistic features, polycystic kidneys
Developmental delay, dysmorphic features (6) (2)
Developmental delay, dysmorphic features, failure to thrive
Developmental delay, hypotonia, obesity
Developmental delay, multiple congenital anomalies
Developmental delay, obesity, congenital facial/neck anomaly
Double outlet right ventricle
Dysmorphic features
Dysmorphic features, ADHD
Encephalopathy (1) (1)
Failure to thrive
Hyperactivity, mixed development disorder
Microtia, hearing loss, agenesis of corpus callosum
Multiple congenital anomalies (1) (2)
Pervasive developmental disorder, dyslalia, learning difficulties
Prader-Willi-like syndrome
Seizure disorder
Speech and language deficits
Speech disturbance
Undersocialized conduct disorder
Numbers in parentheses indicate multiple cases referred for the same indication. Bold cases supplied further clinical information and are included
in the phenotypic analysis. Italicized cases were excluded from phenotypic analysis due to another significant finding on aCGH.
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Fig. 1 High-resolution microarray analysis of 16p11.2 rearrange-
ments. Refinement of 16p11.2 microdeletion breakpoints by high-
density microarray analysis, for a representative set of cases, is shown.
Note that probes with log2 ratios above or below a threshold of 1.5
standard deviations from the normalized mean log2 ratio are colored
green (duplication) or red (deletion), respectively. Dotted lines
represent breakpoint regions (BP). Segmental duplications flanking
the 16p11.2 rearrangements are also shown. The orange and blue
boxes represent homologous segmental-duplication blocks, 147 kb
and 72 kb respectively, participating in the NAHR event for this
particular rearrangement
30 J Neurodevelop Disord (2010) 2:26–38problems, when present, were different than those needed
for ASD diagnosis, including poor attention span and
aggression, and several were specifically reported to be
social and not have any stereotypic behaviors. Mild ASD
features were reported for the remaining nine individuals,
five of whom had a formal ASD evaluation. Of these five,
three received a diagnosis of PDD-NOS, and the other two
did not meet ASD criteria. PDD-NOS diagnoses were given
Table 4 Clinical features identified in individuals in the present and previous studies with 16p11.2 microdeletion
System Clinical finding This report Previous reports
a
(n=18) Frequency (n=35) Frequency
Neurologic Delayed development with below average intelligence 18 100.0% 34 97.1%
Speech & language deficits 17 94.4% 29 82.9%
Hypotonia, with or without hypertonia 7 38.9% 2 5.7%
Strabismus 3 16.7%
Abnormal head imaging 3/9 33.3% 1 2.9%
Seizures or staring spells 2 11.1% 8
b 22.9%
Behavioral Any behavioral problem 14 77.8% 21 60.0%
Poor attention or ADHD 8 44.4% 4 11.4%
Aggression or outbursts 7 38.9% 4 11.4%
ASD or autistic features 9/16 56.3% 16 45.7%
Constitutional Weight ≥ 97th percentile 4 22.2% 9 25.7%
Head Frontal prominence or bossing 5 27.8% 1 2.9%
Face Flattened midface 5 27.8% 9 25.7%
Synophrys 3 16.7%
Bilateral colobomas 1 5.6%
Broad or prominent nose 4 22.2% 3 8.6%
Downturned mouth 3 16.7% 1 2.9%
High palate 3 16.7% 3 8.6%
Micro/retrognathia 4 22.2% 3 8.6%
Ears Hearing loss 3 16.7% 1 2.9%
Fleshy or prominent ears 8 44.4% 1 2.9%
Hypoplastic, simple, or underfolded ears 4 22.2% 3 8.6%
Low-set ears 3 16.7% 3 8.6%
PE tubes 4 22.2% 1 2.9%
Neck Short, thick, or webbed 4 22.2% 4 11.4%
Hands Tapered fingers 4 22.2% 2 5.7%
Abnormal thumbs - proximal, digitalized 2 11.1% 1 2.9%
Feet 2,3 syndactyly 4 22.2% 5 14.3%
Angled great toe or large sandal gap 3 16.7%
Integument Nevi or café au lait spots 5 27.8%
Abnormal fingernails or toenails 6 33.3% 1 2.9%
Heart Abnormal aorta and/or aortic valve 3 16.7% 2 5.7%
Renal Hydronephrosis 2 11.1%
Cystic kidney 1 5.6%
Musculoskeletal Hypermobile joints 4 22.2% 1 2.9%
GI Gastroesophageal reflux disease 5 27.8% 1 2.9%
Pyloric stenosis 1 5.6% 1
c 2.9%
aSubjects reported in (Sebat et al. 2007; Kumar et al. 2008; Weiss et al. 2008; Marshall et al. 2008; Ghebranious et al. 2007; Rosenberg et al.
2006; Shiow et al. 2008; Bijlsma et al. 2009; Fernandez et al. 2009), excluding relatives of probands and those reported in control groups in which
clinical information was not provided
bFebrile seizures were also reported in a brother of a proband who also carried the microdeletion (Fernandez et al. 2009).
cPyloric stenosis was also seen in an uncle of a proband who also carried the microdeletion (Bijlsma et al. 2009).
J Neurodevelop Disord (2010) 2:26–38 31to one female (based on an Autism Diagnostic Observation
Schedule, ADOS) and two males (based on a Childhood
Autism Rating Scale, CARS, one with a score of 30.5, with
the diagnostic cutoff being 30). One female who did not
meet ASD criteria had a CARS score of 24. The ADI-R for
this same female showed mild impairment in social
interactions (score 22) and communication skills (score
15), but she did not have restrictive, repetitive, or
stereotypic patterns of behavior. The other female who did
not meet ASD criteria had an extensive interdisciplinary
developmental evaluation, including observations in multi-
ple settings, and she showed multiple behaviors inconsis-
tent with ASD, including social interactions, varied
interests, and maintenance of conversations. Formal evalu-
ations were not performed on the remaining three males and
one female with features suggestive of ASD, although one
male and one female had been given a PDD-NOS label.
During the study period, we also identified 32 micro-
duplications (0.33% of all cases tested) encompassing
16p11.2 (Table 2). Like the microdeletions, analysis of the
microduplications on ultra-dense tiling arrays confirmed a
548-kb common interval spanning chr16:29559100-
Fig. 2 Physical features in individuals with 16p11.2 microdeletions.
Individuals are aged <1 year a, 2 years b, 3 years c, d, 4 years e, f,
8 years g, 9 years h, 10 years i, j, 18 years k and 20 years l. m Foot of
individual shown in (k). Note 2–3 syndactyly and small toenails. n
Profile of individual shown in (g). Note hypoplastic ear with
Darwinian tubercle and fleshy lobe. Ears are also fleshy and/or
prominent in individuals (b, e, i, j). Individual (g) also has bilateral iris
coloboma. Other features noted include frontal bossing (f, j, k),
flattened midface (h, j, k), broad nose (b, e), retrognathia (a, j, k),
short, thick, or webbed neck (e, g, j), downturned mouth (e, g, h) and
synophrys (k, j)
32 J Neurodevelop Disord (2010) 2:26–3830107210 (Hg18) with breakpoints that were all within the
flanking segmental duplications (Fig. 1). Three (0.37%) of
the 820 individuals with an ASD as the indication for study
had the microduplication. Four of these 32 individuals had
another clinically significant finding on aCGH and were
excluded from further study (Table 5).
Among the 32 individuals with the 16p11.2 micro-
duplication, 24 maternal samples and 15 paternal samples
were tested, and inheritance was determined in 19 individ-
uals. The microduplication was de novo in five individuals
(26%), maternally inherited in nine (47%) and paternally
inherited in five (26%). Information was available on four
mothers and two fathers. One mother had childhood
seizures and intermittent hypoglycemia; another had sus-
pected multiple sclerosis; a third mother had speech
articulation problems, mood swings, depression, anxiety,
pain, and bouts of head banging when upset; a fourth
mother had learning disabilities. One father had childhood
seizures, delays, and ADHD-like features, and the other
father was described as autistic-like.
Detailed clinical information was available for 10
individuals with microduplications in our cohort (Table 6,
Table S4). Three of these individuals had clinical
diagnoses—Beckwith-Wiedemann syndrome, PKU and
methylmalonic aciduria—likely independent of the micro-
duplication. Two individuals had a history of abuse, causing
physical or psychological trauma that could have resulted in
subsequent behavioral issues, complicating conclusions
about the phenotype associated with the microduplication.
Minimal dysmorphic features were reported in these patients,
with epicanthal folds (70%) and a broad or prominent nose
(40%) the most common features (Fig. 3). Only one
individual had a heart abnormality, a patent ductus arteriosus
(PDA), although a sister of one of these individuals had a
ventricular septal defect (VSD) and was found to have the
microduplication. Another individual had congenital dia-
phragmatic hernia (CDH), horseshoe kidneys and malrota-
tion, which was interpreted as a field defect. A majority of
individuals had delayed development (80%), with the same
number reporting specific deficits in speech or language
(80%). Behavior problems were present in half, with four out
of five individuals with behavior problems showing aggres-
sion or outbursts. Of the eight individuals with micro-
duplications old enough to be evaluated for autism, none had
formal ASD evaluation, although one male had a suspected
diagnosis of PDD-NOS or autism.
Discussion
The 16p11.2 microdeletion (n=45) and microduplication
(n=32) represent 3.1% of all abnormalities reported by our
laboratory, second only to the 22q11.2 velocardiofacial/
DiGeorge syndrome region (n=60 deletions and 22
duplications; 3.3% of all abnormalities). During this same
period, we identified 13 Smith-Magenis syndrome (SMS)
deletions (population frequency of ~1/15,000) (Elsea and
Girirajan 2008) and 28 Williams syndrome deletions
(population frequency of ~1/7,500) (Stromme et al. 2002),
suggesting the population frequency of 16p11.2 micro-
deletions may be greater than 1/5,000 and the micro-
duplication greater than 1/7,500. These may be
overestimates of frequency because some cases of SMS
and Williams syndrome are diagnosed by other methods,
and therefore not all individuals with these syndromes will
have aCGH, while 16p11.2 abnormalities would not be
expected to be diagnosed by other methods. Conducting
Fisher’s exact test to compare our population to our group
of 2493 controls (Itsara et al. 2009), in which no micro-
deletions were found and one microduplication was found
(Table 1), yields a two-tailed p of 5.2 × 10
−5 for the
microdeletion and an odds ratio of 8.19 and two-tailed p of
0.0084 for the microduplication. Therefore, both the
microdeletion and microduplication have a significantly
higher frequency in our patient population when compared
Table 5 Indications for study in 32 individuals found to have the
16p11.2 microduplication
46,XY,add(11)(p15)
Bilateral tremors
Cerebral palsy
Developmental delay (2) (2) (2)
Developmental delay, ADHD, fetal alcohol syndrome
Developmental delay, autism, mental retardation, tall, thin
Developmental delay, behavior disturbance
Developmental delay, dysmorphic features (2) (2)
Developmental delay, multiple congenital anomalies
Developmental delay, seizure disorder
Developmental delay, seizure disorder, autism
Developmental delay, seizure disorder, autistic disorder
Dysmorphic features
Dysmorphic features, multiple congenital anomalies
Encephalopathy (1) (1)
Failure to thrive
Mental retardation, facial and neck anomalies
Multiple congenital anomalies
Not specified
Seizure disorder
Tracheoesophageal fistula
Thyrotoxicosis
Tremors
Numbers in parentheses indicate multiple cases referred for the same
indication. Bold cases supplied further clinical information and are
included in the phenotypic analysis. Italicized cases were excluded
from phenotypic analysis due to another significant finding on aCGH.
J Neurodevelop Disord (2010) 2:26–38 33to our control group. We conducted a review of these
individuals’ phenotypes to better understand the features
associated with these recurrent genomic alterations.
Observation of our cohort suggests that language delays
and behavior problems are common among individuals
with 16p11.2 microdeletions, which is consistent with
previous reports (Kumar et al. 2008; Weiss et al. 2008;
Marshall et al. 2008; Ghebranious et al. 2007; Rosenberg et
al. 2006; Shiow et al. 2008; Bijlsma et al. 2009; Fernandez
et al. 2009), although some reports have suggested that
cognitive or behavioral impairment may be present without
speech delay (Sebat et al. 2007; Weiss et al. 2008;
Ghebranious et al. 2007; Bijlsma et al. 2009). While some
patients have dysmorphic features, others are specifically
nondysmorphic (Kumar et al. 2008; Weiss et al. 2008;
Marshall et al. 2008; Ghebranious et al. 2007; Rosenberg et
al. 2006; Bijlsma et al. 2009; Fernandez et al. 2009), and
there is no recognizable facial gestalt. There may be an
association with aortic or aortic valve abnormalities, seen in
three individuals in our report and a set of twins in the
literature (Ghebranious et al. 2007). Pyloric stenosis may
also be infrequently associated with this microdeletion,
seen in one individual in our report and two others in the
literature (Bijlsma et al. 2009). Seizures were present in two
individuals in our cohort, which is less frequent than
previously reported, particularly in ASD cohorts (Kumar et
al. 2008; Weiss et al. 2008; Ghebranious et al. 2007;
Fernandez et al. 2009).
It is difficult to ascertain a common phenotype among
individuals with 16p11.2 microduplications, and it is further
complicated by the presence of other diagnoses and
complicated social histories in patients in our cohort.
Furthermore, we have an ascertainment bias, as we are
only testing individuals whose phenotype is suggestive of a
System Clinical finding This report Previous reports
a
(n=10)
b (n=16)
Neurologic Delayed development and/or below average intelligence 8 16
Speech & language deficits 8 14
Hypotonia, with or without hypertonia 4 2
Strabismus 2
Abnormal MRI 4/6 1
Seizures or staring spells 1 2
Behavioral Any behavioral problem 5 12
Poor attention or ADHD 3
Aggression or outbursts 4
ASD or autistic features 1/8 11
Head Frontal prominence or bossing 2 1
Microcephaly 3
Anterior hair whorl/asymmetric hair whorl 3
Face Epicanthal folds 7
Telecanthus or hypertelorism 3
Downslanting palpebral fissures 3
Broad or prominent nose 4
Shallow nasal bridge 2
Micro/retrognathia 2
Ears Preauricular pits 3
Prominent ears 2
Back Sacral dimple 2
Feet Third toe curvature 2
Integument Nevi or café au lait spots 2
Diaphragm Congenital diaphragmatic hernia 1 1
Heart Patent ductus areteriosus 1
Renal Reflux 2
Horseshoe kidney 1
Duplicated collecting system 1
GI Gastroesophageal reflux disease 3
Malrotation 1
Table 6 Clinical features
identified in individuals in the
present and previous studies
with 16p11.2 microduplication
aSubjects reported in
(Fernandez et al. 2009; Kumar
et al. 2008; Marshall et al. 2008;
Weiss et al. 2008), excluding
those reported in control groups
whose clinical information was
not provided and two subjects
with childhood-onset schizo-
phrenia without further clinical
information (Walsh et al. 2008)
bSome subjects in this
report had other factors compli-
cating the phenotype, including
other genetic diagnoses
(Beckwith-Wiedemann, PKU,
and methylmalonic aciduria)
and complicated social histories.
34 J Neurodevelop Disord (2010) 2:26–38genetic condition. The literature has reports of this micro-
duplication in a variety of individuals. While most micro-
duplications have been found from screening cohorts of
autistic individuals, they have also been found in parents, in
individuals with bipolar disorder, in individuals with
schizophrenia and in controls (Table 1) (Kumar et al.
2008; Weiss et al. 2008; Fernandez et al. 2009; Walsh et al.
2008). In previous studies, microduplications were usually,
but not always, found in a higher frequency in abnormal
cohorts than in normal controls (Table 1); our cohort does
show a significant increase in this frequency. Speech and/or
motor delay is seen in a majority of individuals in our
cohort and has been reported in other individuals (Weiss et
al. 2008; Fernandez et al. 2009). Behavior problems may be
associated with this microduplication, observed in half of
the individuals in our cohort and in those in the literature
from ASD cohorts (Kumar et al. 2008; Weiss et al. 2008;
Marshall et al. 2008; Fernandez et al. 2009). Similar to the
microdeletion, individuals with the microduplication may
not have dysmorphic features (Weiss et al. 2008; Marshall
et al. 2008; Fernandez et al. 2009), and dysmorphic features
are not consistent among individuals. The only major
m a l f o r m a t i o ns e e ni nm o r et h a no n ei n d i v i d u a li sa
congenital diaphragmatic hernia, one in our cohort and
one in a previous report (Marshall et al. 2008; Fernandez et
al. 2009).
Inheritance of 16p11.2 microdeletions and microduplia-
tions is notably different, with a majority of microdeletions
being de novo and the majority of microduplications being
inherited. A combination of our report with those in the
literature shows a de novo microdeletion in 36/50 (72%) of
families with known inheritance (de novo microdeletions
have been found in two sets of monozygotic twins and in
two sibs due to paternal germline mosaicism). Including our
cases, this microdeletion has been described in eight
parents—three fathers and five mothers—with various
developmental problems and in five apparently normal
parents, one father and four mothers (Sebat et al. 2007;
Weiss et al. 2008; Marshall et al. 2008; Ghebranious et al.
2007; Shiow et al. 2008; Bijlsma et al. 2009; Fernandez et
al. 2009). In contrast, a combination of our report with
those in the literature shows a de novo microduplication in
7/28 (25%) of families with known inheritance. Inheritance
is mixed—maternal in twelve, paternal in seven and
unspecified in two (Kumar et al. 2008; Weiss et al. 2008;
Marshall et al. 2008; Fernandez et al. 2009; Walsh et al.
2008). Phenotypic information is unavailable for a majority
of parents in our cohort, and the three parents with the
microduplication in the literature who have been described
include a mother with learning disabilities, a father with
bipolar disorder, and a mother with depression, anxiety,
learning disabilities and behavior problems who also carried
a 1-Mb deletion on 7q31.2 (Kumar et al. 2008; Fernandez et
al. 2009). An apparently healthy 8-year-old sister of a
proband who also carried the microduplication has been
described (Fernandez et al. 2009). Compared to micro-
deletions, the greater number of inherited microduplications
suggests this alteration is more likely to be passed on to
subsequent generations, which could be due to a less-severe
phenotype caused by the microduplication. While our report
and the literature show a majority of the inherited micro-
deletions and microduplications are from mothers, in our
cohort, this is likely due to the greater availability of
maternal samples. Therefore, there is no current evidence
for a parent-of-origin bias or imprinting of this region.
Because individuals with 16p11.2 alterations commonly
have speech delays and behavior problems, their features
may be more likely to arouse clinical suspicion of ASD
than individuals without similar neurodevelopmental prob-
lems. However, some of the individuals in our cohort were
not considered to have autistic features. Additionally, while
we found 16p11.2 abnormalities more commonly among
individuals referred for ASD, this difference was not
significant (Table 2). These groupings are not precise,
however, as they are based on indications for study, which
are commonly inaccurate or incomplete. Several cases
without an ASD in the indication for study were determined
Fig. 3 Physical features in individuals with 16p11.2 microduplica-
tions. a, b 7-year-old male with epicanthal folds, broad nose, frontal
hair whorl, wide mouth and low-set ears. c, d, e Siblings aged 6, 2,
and their mother (age 38), all of whom have a 16p11.2 micro-
duplication. Note thin upper lip and prominent forehead
J Neurodevelop Disord (2010) 2:26–38 35to have an ASD, and one with an indication for study of
autism specifically did not meet criteria for an ASD
diagnosis. Our study is also limited by the lack of rigorous
phenotypic analysis for all patients, especially for ASD.
However, it is likely that other factors are required in these
individuals to cause the development of ASD, a hypothesis
supported by reports in the literature of families with
16p11.2 microdeletions and microduplications (Fernandez
et al. 2009; Glessner et al. 2009). This microdeletion has
been reported in single autistic individuals and not in their
affected siblings in four multiplex families (Kumar et al.
2008; Marshall et al. 2008; Fernandez et al. 2009). The
microduplication has been found in multiple affected
siblings in two families and in unaffected siblings in two
families, but it has not been found in affected siblings in
one family (Weiss et al. 2008; Marshall et al. 2008;
Fernandez et al. 2009). In our report, there is a 2-year-old
male with a microduplication and suspected ASD diagnosis
with a sister with mild PDD-NOS, a brother with anger
issues and emotional lability and a mother with behavioral
abnormalities (head banging), depression and anxiety. The
mother and sister were found to have the microduplication,
whereas the brother did not (Fig. 3). In some of these
previously reported individuals, the siblings without the
microdeletion are more severely affected in some aspect of
their behavior or development (Fernandez et al. 2009). Of
the three AGRE multiplex families with affected children
discordant for the 16p11.2 microdeletion, the sibling
without the microdeletion has later speech development in
two families, and in the third family the sibling without the
microdeletion has a higher Autism Diagnostic Interview-
Revised (ADI-R) communication score than his brother,
indicating greater impairment (Kumar et al. 2008). Two
families also show a higher ADI-R social score in the
sibling without the microdeletion. In addition, in one pair of
siblings who both have the 16p11.2 microdeletion, the
sister has higher ADI-R and ADOS scores than her brother
in most categories (Kumar et al. 2008; Weiss et al. 2008);
because females are the less-affected sex, it would be
predicted that in a male and female with the same genetic
factors for autism, the male would be more severely affected.
Consistent with males being the more susceptible gender, two
families that are not part of the AGRE cohort have been
reported, both of which have a son and daughter affected with
ASD,withthesonhavingamoreseverephenotype.However,
in one case, the daughter has the 16p11.2 microdeletion, and
in the other the son has the microdeletion (Fernandez et al.
2009). These multiplex families suggest factors, genetic and/
or environmental, other than the 16p11.2 alteration play a
role in the children’sa u t i s t i cf e a t u r e s .
Glessner et al. have also suggested that 16p11.2
alterations may not be sufficient to cause ASD, citing the
discordance in these multiplex families in the literature as
well as a non-significant difference between ASD cases and
controls in their cohort (Glessner et al. 2009). Our study
differs from this in finding a significant increase of the
16p11.2 microdeletion and microduplication among indi-
viduals undergoing clinical aCGH testing as compared to
controls. This difference may be due to the fact that their
report included smaller deletions and duplications within
the 16p11.2 region and/or to their use of children as
controls. Of note, a subsequent publication of their control
group does not contain any abnormalities in this region
(Shaikh et al. 2009).
Microdeletions and microduplications of the 16p11.2
region are emerging as common findings in individuals
with developmental delay, although the phenotypic con-
sequences are only beginning to be understood. In our
study population, the microdeletions and microduplications
are associated with a high frequency of cognitive, devel-
opmental and speech delay and behavior issues, with the
microdeletions showing a higher incidence of these features
than the microduplications. Although 16p11.2 abnormali-
ties have mostly been identified in ASD cohorts, our cohort
demonstrates a phenotypic range from behavioral problems
that were not considered autistic to formal diagnoses of
PDD-NOS in three individuals, suggestive of a spectrum of
developmental and speech delays and behavioral issues that
overlaps with ASD. The disparity in numbers of individuals
with ASD among cohorts may be the result of differences
in study inclusion criteria. Because the microdeletion and
microduplication have been reported in normal individuals
and controls and demonstrate phenotypic variability in
families, additional genetic or environmental factors may be
required for manifestation of clinical features. Further
studies of individuals with 16p11.2 microdeletions and
microduplications from control populations and populations
with a variety of abnormal phenotypes are necessary to
increase the understanding of these genomic alterations and
their associated phenotypes.
Subjects and methods
Ethics statement
Consent for publication of photographs was obtained for
the individuals with 16p11.2 microdeletions and micro-
duplications shown here.
Subjects and controls
From November 2007 through October 2008, we per-
formed microarray analysis on 9,773 consecutive individ-
uals whose specimens were submitted to Signature
Genomic Laboratories, with indications for study including
36 J Neurodevelop Disord (2010) 2:26–38developmental delay, dysmorphic features, congenital
anomalies, and/or seizures. The indication for study was
autism, autistic features, pervasive developmental delay
(PDD), or Asperger syndrome in 820 of these samples.
Referring physicians of individuals found to have 16p11.2
microdeletions or microduplications were contacted to help
coordinate release of clinical information for publication.
The control set consisted of 2493 individuals whose
copy-number variations had been identified using Illumina
SNP microarrays in the author’s( E E ’s) laboratory as
d e s c r i b e di nI t s a r ae ta l .( 2009) These included 936
middle-age (40–70 years) individuals living in the United
States being tested as part of statin trials and cholesterol;
671 National Institute of Neurological Disorders and Stroke
(NINDS) samples of European descent with no family
history of or any first-degree relative with amyotrophic
lateral sclerosis, ataxia, autism, brain aneurysm, dystonia,
Parkinson disease or schizophrenia and 886 individuals
sampled from 51 different world populations as part of the
HGDP collection.
BAC microarray analysis
Microarray-based comparative genomic hybridization
(aCGH) was performed on some individuals with a
bacterial artificial chromosome (BAC) microarray (the
SignatureChipWG®; Signature Genomic Laboratories, Spo-
kane, WA) as previously described (Ballif et al. 2008a;
Bejjani et al. 2005).
Oligonucleotide aCGH
Oligonucleotide-based microarray analysis was performed
on some individuals using a 105 K-feature whole-genome
microarray (SignatureChip Oligo Solution™,m a d ef o r
Signature Genomic Laboratories by Agilent Technologies,
Santa Clara, CA) as previously described (Ballif et al.
2008b).
CNV validation by high-resolution aCGH
Further refinement of 16p11.2 CNV breakpoints were
performed by custom high-density oligonucleotide arrays
(NimbleGen Systems). The high-density array consisted of
a total 135,000 isothermal probes (45–75 bp) including
120,146 probes covering a 4-Mb 16p11.2 region (chr16:
27,500,000 to 31,500,000) with a mean spacing 1 probe
every 19 bp. As a control for probe hybridizations and for
normalizing the array data, we also included 15,118 probes
to a 7.5-Mb 16p12 region with a mean probe spacing of
451 bp. All microarray hybridization experiments were
performed as described previously (Selzer et al. 2005), using
a single unaffected male (GM15724, [Corriell]) as reference.
Fluorescence in situ hybridization
All 16p11.2 microdeletions detected by array CGH were
confirmed and visualized by metaphase fluorescence in situ
hybridization (FISH) BAC clones CTD-3159M2 or CTD-
2515O10 (Shaffer et al. 1994). Parental samples for
individuals with microdeletions were assayed by FISH.
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